Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Landiolol hydrochloride - Ono Pharmaceutical

Drug Profile

Landiolol hydrochloride - Ono Pharmaceutical

Alternative Names: Corebeta; Landiolol hydrochloride; ONO-1101; Onoact

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Class Antiarrhythmics; Morpholines; Small molecules; Urea compounds
  • Mechanism of Action Beta 1 adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ventricular fibrillation; Ventricular tachycardia; Arrhythmias
  • New Molecular Entity No

Highest Development Phases

  • Marketed Arrhythmias; Supraventricular tachycardia; Ventricular arrhythmias
  • Phase II/III Atrial fibrillation; Atrial flutter

Most Recent Events

  • 24 Jan 2023 Launched for Arrhythmias (In adolescents, In children, In infants, In neonates) in Japan (IV)
  • 24 Jan 2023 Registered for Arrhythmias (In adolescents, In children, In infants) in Japan (IV) before January 2023
  • 24 Jan 2023 As of January 2023, Landiolal hydrochloride receives approval for Tachyarrythmia in paediatric patients with low cardiac function in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top